EUS-guided fine needle aspiration market seen reaching $1.06B by 2030

The Business Research Company says the EUS-guided fine needle aspiration market will grow from $0.7 billion in 2025 to $1.06 billion by 2030, driven by rising pancreatic and gastrointestinal cancer cases and demand for minimally invasive diagnostics. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - EUS-guided fine needle aspiration is a minimally invasive diagnostic tool used to sample tissue from deep internal organs such as the pancreas, lymph nodes and liver. - Growth in the market signals rising demand for earlier cancer detection and less invasive procedures in gastroenterology and oncology. - The market outlook also reflects broader pressure from pancreatic disorders and increasing diabetes cases.

What happened: - The Business Research Company released its "Endoscopic Ultrasound (EUS)-Guided Fine Needle Aspiration Market Report 2026 – Market Size, Trends, And Forecast 2026-2035." - The report puts the market at $0.7 billion in 2025 and $0.76 billion in 2026. - The report forecasts the market will reach $1.06 billion by 2030. - The company said the market is expanding at an 8.6% CAGR in 2026 and is projected to grow at 8.7% through 2030. - A free sample of the report is available here. - The full report is available here.

The details: - EUS-FNA combines ultrasound imaging with a fine needle to collect tissue or fluid samples from internal organs. - The procedure uses a thin needle passed through an ultrasound-equipped endoscope. - The technique helps physicians diagnose cancers, cysts and other abnormalities without extensive surgery. - The report cites limited supply of specialized EUS-FNA needles, reliance on traditional biopsy techniques, rising awareness of early cancer detection, wider hospital and clinic adoption, and improved standardization of endoscopic ultrasound practices as recent growth factors. - Forecasted growth is tied to powered EUS-FNA needle innovation, higher incidence of pancreatic and gastrointestinal cancers, expansion in gastroenterology and oncology specialties, stronger demand for minimally invasive diagnostics, and integration with imaging and robotic systems. - Key trends include broader use in oncology and gastroenterology, development of powered and manual needle options, growth in specialty clinics and ambulatory surgical centers, and a focus on improving sample accuracy while reducing patient discomfort. - The report says increasing prevalence of pancreatic disorders is a major growth driver. - Pancreatic disorders include inflammation, tumors and functional impairments that affect digestion and hormone regulation. - EUS-FNA supports diagnosis of pancreatic lesions, cancers, cysts and chronic pancreatitis. - Cancer Australia data cited in the report show pancreatic cancer deaths rose from 3,687 in 2022 to 3,902 in 2024.

Between the lines: - The market story is less about one device category and more about the shift toward earlier, safer diagnosis in hard-to-reach cancers. - The forecast suggests hospitals and specialty clinics are moving toward procedures that can reduce surgical burden and speed diagnosis. - The report’s emphasis on robotics, imaging and powered needles points to a market that is still in a technology-upgrade phase rather than a mature cycle.

What's next: - The report expects Asia-Pacific to post the fastest growth through the forecast period. - North America held the largest market share in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The Business Research Company also listed its LinkedIn page and social media channels for follow-up information.